Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis

References

• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   Google Scholar
• James ND, De Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351.
   Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019 Jul 4;381(1):13–24.
   Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
   Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019 Nov 10;37(32):2974–2986.
   Google Scholar
• Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec;392(10162):2353–2366.
   Google Scholar
• Fizazi K, Maldonado X, Foulon S, et al. A phase 3 trial with a 2x2 factorial design of Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first results of PEACE-1. J Clin Oncol. 2021;39(15): 5000-5000. DOI:10.1200/JCO.2021.39.15_suppl.5000.
   Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Update. 2020;
   Google Scholar
• Lowrance WT, Breau RH, and Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2020 205 1 22–29 doi:10.1097/JU.0000000000001376 .
   Google Scholar
• NCCN Guidelines for prostate cancer [Internet]. [cited 2020 Dec 3]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18(4):284–294.
   Google Scholar
• Eisenhauer EA, Therasse P, and Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 45 2 228–47 doi:10.1016/j.ejca.2008.10.026 .
   Google Scholar
• National Institute of Health. National cancer institute common terminology criteria for adverse events (CTCAE) version 5.0. NIH Publication. 2017.
   Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, Open-label, Phase 3 trial. Lancet Oncol. 2013;14(2):149–158.
   Google Scholar
• Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020 Dec 15;8(2):209–230.
   Google Scholar
• Sydes MR, Spears MR, Mason MD, et al. Adding Abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–1248.
   Google Scholar